Page last updated: 2024-11-13

sy 5555

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SUN 5555: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	23663972
CHEMBL ID	431753
SCHEMBL ID	4777178
MeSH ID	M0167096

Synonyms (38)

Synonym
wy-49605
ru-67655
sy-5555
sun-5555
alp-201
furopenem
bla-857
ym-044
fropenem sodium
fropenum sodium
sun 5555
farom
sy5555
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, monosodium salt, (5r-(3(r),5-alpha,6-alpha(r)))-
(5r,6s)-6-(1(r)-hydroxyethyl)-2-(2(r)-tetrahydrofuryl)penem-3-carboxylic acid monosodium salt
alp 201
ccris 6723
CHEMBL431753
sy 5555
unii-7o46g914rq
7o46g914rq ,
wy 49605
AKOS015896069
CS-M0814
sodium (+)-(5r,6s)-6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate
faropenem sodium [mart.]
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, sodium salt (1:1), (5r,6s)-
faropenem sodium salt [mi]
faropenem sodium salt
faropenem sodium [who-dd]
F-0950
faropenem sodium, antibiotic for culture media use only
SCHEMBL4777178
sodium (5r,6s)-6-((r)-1-hydroxyethyl)-7-oxo-3-((r)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
HY-76260
sodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
CCG-267545
F85590

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" Using a physiologically based pharmacokinetic model, unbound concentrations of SUN5555 in the tissue interstitial fluids, which are the measure of in vivo antibacterial efficacy, were estimated to be almost identical with, or higher than, those in plasma in rats."	( Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. Adachi, H; Ishiguro, M; Nishihara, T; Noguchi, T; Ohnuma, N; Sato, H; Tamai, I; Tsuji, A, )	0.13
"Bacteriological, pharmacokinetic and clinical studies on SY5555 dry syrup (powder which is dissolved before use), a new penem antibiotic for oral use, were performed."	( [Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. Ishihara, T; Nakamura, H; Tezuka, T; Toyonaga, Y, 1995)	0.29
" Pharmacokinetic and clinical studies using SY5555 dry syrup (powder which is dissolved before use) were performed in pediatric patients."	( [Pharmacokinetic and clinical studies on SY5555 dry syrup in children]. Fukuda, T; Gondou, I; Harada, Y; Hayashi, K; Kido, T; Kobayashi, N; Matsumoto, T; Tsuji, Y; Uchida, T; Uehara, Y, 1995)	0.29

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID69660	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Escherichia coli KC-14/RGN 823	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID206011	Minimum inhibitory concentration was determined in heart infusion agar medium against Staphylococcus aureus(MRSA)	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID69659	Minimum inhibitory concentration was determined in heart infusion agar medium against Escherichia coli NIHJ JC-2	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID203164	Minimum inhibitory concentration was determined in heart infusion agar medium against Serratia marcescens IAM 1136	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID164585	Minimum inhibitory concentration was determined in heart infusion agar medium against Pseudomonas aeruginosa PAO-1	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID68536	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Enterobacter cloacae NTCC9394	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID206010	Minimum inhibitory concentration was determined in heart infusion agar medium against Staphylococcus aureus 209P JC-1	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID93901	Minimum inhibitory concentration was determined in heart infusion agar medium against Klebsiella pneumoniae PCI 602	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID163424	Minimum inhibitory concentration was determined in heart infusion agar medium against Proteus vulgaris GN 7919	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID67760	Minimum inhibitory concentration was determined in heart infusion agar medium against Enterococcus faecalis ATCC 19433	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID50538	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Citrobacter freundii GN7391	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID40800	Minimum inhibitory concentration was determined in heart infusion agar medium against Bacillus subtilis ATCC 6633	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (8.82)	18.7374
1990's	31 (91.18)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	18 (51.43%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	2 (5.71%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (42.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cefuroxime Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.	6.98	1	0	carbamate ester; cephalosporin
cefixime Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.. cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.	7.68	3	0
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	6.98	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	7.39	2	0	penicillin allergen; penicillin	antibacterial drug
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.68	3	0	cephalosporin	antibacterial drug; drug allergen
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	2.68	3	0	cephalosporin	fungal metabolite
fropenem [no description available]	1.99	1	0	faropenem
cefminox cefminox : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and 2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido side-groups located respectively at positions 3 and 7beta of the cephem nucleus. A broad-spectrum bactericide, it is especially effective against Gram-negative and anaerobic bacteria.	1.98	1	0	cephamycin; tetrazoles
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.39	2	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
carbapenems [no description available]	8.82	33	18
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	2.68	3	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
cefmenoxime Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmenoxime : A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.	1.98	1	0	cephalosporin	antibacterial drug
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	2.39	2	0
cefdinir Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.. cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.	1.98	1	0
cefteram cefteram: structure given in first source. cefteram : A cephalosporin compound having (5-methyl-2H-tetrazol-2-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a third-generation cephalosporin antibiotic.	1.98	1	0

Condition	Relationship Strength	Studies	Trials
Infections, Respiratory [description not available]	6.58	8	7
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	6.58	8	7
Bacterial Disease [description not available]	8.19	18	17
Impetigo Contagiosa [description not available]	4.34	2	2
Bacterial Infections Infections by bacteria, general or unspecified.	8.19	18	17
Impetigo A common superficial bacterial infection caused by STAPHYLOCOCCUS AUREUS or group A beta-hemolytic streptococci. Characteristics include pustular lesions that rupture and discharge a thin, amber-colored fluid that dries and forms a crust. This condition is commonly located on the face, especially about the mouth and nose.	4.34	2	2
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	6.71	8	8
Eosinophilia, Tropical [description not available]	3.37	1	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	4.34	2	2
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	3.37	1	1
Scarlet Fever Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present.	4.34	2	2
Middle Ear Inflammation [description not available]	3.37	1	1
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	3.37	1	1
Bacterial Skin Diseases [description not available]	3.37	1	1
Skin Diseases, Bacterial Skin diseases caused by bacteria.	3.37	1	1
Bacterial Infections, Gram-Positive [description not available]	3.37	1	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	3.37	1	1

chemdatabank.com